跳转至内容
Merck

Y0000837

氨苯蝶啶

European Pharmacopoeia (EP) Reference Standard

别名:

2,4,7-Triamino-6-phenylpteridine, 6-Phenyl-2,4,7-pteridinetriamine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H11N7
CAS号:
分子量:
253.26
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

triamterene

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1

InChI

1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)

InChI 密鑰

FNYLWPVRPXGIIP-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Triamterene EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A Haris et al.
Orvosi hetilap, 137(35), 1907-1914 (1996-09-01)
The group of drugs, so-called "potassium sparing diuretics" represent an important part of our modern therapeutic arsenal. Their "weak diuretic" properties are especially beneficial in cirrhotic patients with ascites, when highly effective loop diuretics may be hazardous. Potassium sparing diuretics
H Priewer et al.
Die Pharmazie, 52(3), 179-181 (1997-03-01)
This work represents a summary of studies carried out with potassium and magnesium retaining triamterene derivatives. The synthesis, analytics and physico-chemical characteristics of those substances are described. Furthermore, the relationships between the chemical structure and electrolyte excretion, pharmacokinetics, metabolism and
C Lucas et al.
Journal d'urologie, 88(1), 37-42 (1982-01-01)
Various studies have demonstrated a relationship between nephrolithiasis and the ingestion of certain drugs. We are particularly interested in the effects of triamterene. Five published case studies on patients of both sexes between 43 and 60 years of age have
[Pharmacology of potassium-sparing diuretics: amiloride and triamterene].
G Rorive et al.
Coeur et medecine interne, 17(2), 207-215 (1978-04-01)
R A Carey et al.
Clinical therapeutics, 6(3), 302-309 (1984-01-01)
A small number of patients taking products containing triamterene (TAT) develop renal calculi that contain TAT and its metabolites. Most TAT-containing calculi are composed of various crystalline materials, but a small number consist only of TAT, its metabolites, and a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门